MiNK Therapeutics jumps on pediatric cancer collaboration and non-dilutive funding news

MiNK Therapeutics (INKT) is up 41.9% today. Here is some analysis on what might have caused this price movement.

Analysis: The rally appears tied to MiNK announcing a new pediatric oncology collaboration that provides non-dilutive funding and advances a PRAME-targeted engineered iNKT cell therapy program. For a small-cap biotech like MiNK, partnership-style validation and any incremental financing clarity can have an outsized impact on the stock.

Details:

MiNK announced a strategic collaboration with the C-Further pediatric oncology consortium to develop a PRAME-targeted TCR-engineered iNKT cell therapy for pediatric cancers.

The agreement includes up to about $1.1 million in non-dilutive aggregate payments to support IND-enabling work, with milestone-based payments as development progresses.

MiNK disclosed potential “double-digit” downstream commercial revenue participation tied to the program’s future success, while keeping the collaboration non-exclusive.

Researchers at the University of Southampton are expected to conduct comparative preclinical studies (activity, persistence, and safety) to help select a lead candidate for advancement toward first-in-human studies.

Sources:

Globe Newswire, Investing.com, Benzinga

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$INKT Insider Trading Activity

$INKT insiders have traded $INKT stock on the open market 2 times in the past 6 months. Of those trades, 0 have been purchases and 2 have been sales.

Here’s a breakdown of recent trading of $INKT stock by insiders over the last 6 months:

BARBARA RYAN has made 0 purchases and 2 sales selling 500 shares for an estimated $5,425.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

$INKT Hedge Fund Activity

We have seen 9 institutional investors add shares of $INKT stock to their portfolio, and 7 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

VANGUARD GROUP INC added 34,300 shares (+102.8%) to their portfolio in Q4 2025, for an estimated $382,445
DRW SECURITIES, LLC added 25,677 shares (+inf%) to their portfolio in Q4 2025, for an estimated $286,298
NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO added 7,755 shares (+40815.8%) to their portfolio in Q4 2025, for an estimated $86,468
RENAISSANCE TECHNOLOGIES LLC removed 4,200 shares (-28.8%) from their portfolio in Q4 2025, for an estimated $46,830
UBS GROUP AG added 3,900 shares (+69.1%) to their portfolio in Q4 2025, for an estimated $43,485
GEODE CAPITAL MANAGEMENT, LLC added 1,441 shares (+11.3%) to their portfolio in Q4 2025, for an estimated $16,067
TOWER RESEARCH CAPITAL LLC (TRC) removed 631 shares (-68.1%) from their portfolio in Q4 2025, for an estimated $7,035

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.